Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The Lancet Oncology - Tập 18 - Trang 31-41 - 2017
Matthew D Hellmann1, Naiyer A Rizvi1, Jonathan W Goldman2, Scott N Gettinger3, Hossein Borghaei, Julie R Brahmer4, Neal E Ready5, David E Gerber6, Laura Q Chow7, Rosalyn A Juergens8, Frances A Shepherd9, Scott A Laurie10, William J Geese11, Shruti Agrawal11, Tina C Young12, Xuemei Li12, Scott J Antonia13
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
2UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
3Yale Comprehensive Cancer Center, New Haven, CT, USA
4Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
5Duke University Medical Center, Durham, NC, USA
6UT Southwestern Medical Center, Dallas, TX, USA
7University of Washington, Seattle, WA, USA
8Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
9Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
10Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada
11Bristol-Myers Squibb, Princeton, NJ, USA.
12Bristol Myers Squibb, Princeton, NJ, USA
13H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 18

31-41

Thông tin tác giả